<DOC>
	<DOCNO>NCT00780494</DOCNO>
	<brief_summary>To investigate bevacizumab combination carboplatin capecitabine patient unresectable metastatic GEJ gastric cancer . We hope add bevacizumab standard chemotherapy patient population improve Progression Free Survival 80 % historical control .</brief_summary>
	<brief_title>Ph II Capecitabine , Carboplatin &amp; Bevacizumab Gastroesophageal Junction &amp; Gastric Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subjects must treat Stanford University Medical Center entire length study participation . 1 . Patients histologically cytologically confirm adenocarcinoma GEJ stomach . 2 . Patients must deem unresectable due involvement critical vasculature adjacent organ invasion . If unresectable , patient must show evidence disease progression prior enrollment . 3 . Patients prior surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval &gt; 5 year elapse primary surgery development metastatic disease . Clinicians consider biopsy lesion establish diagnosis metastatic disease substantial clinical ambiguity regard nature source apparent metastasis . 4 . Prior carboplatin neoadjuvant adjuvant therapy allow &gt; = 6 month time study entry . 5 . If patient use aspirin ( &gt; 325mg/day ) NSAIDS time enrollment , must 10 day washout period prior begin protocol treatment . 6 . Low molecular weight heparin ( equivalent , exclude warfarin ) allow treatment venous thromboembolic event patient evidence bleed fulldose anticoagulation . 7 . Patients must primary metastatic lesion measurable least one dimension Modified RECIST criterion ( see Section 11.2.3 ) within 4 week prior entry study 8 . Patients must ECOG performance status 01 9 . Patients must &gt; = 18 year age 10 . Laboratory value &lt; = 2 week prior randomization : Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 109/L ( &gt; = 1500/mm3 ) Platelets ( PLT ) &gt; = 100 x 109/L ( &gt; = 100,000/mm3 ) Hemoglobin ( Hgb ) &gt; = 9 g/dL Serum creatinine &lt; = 1.5 x ULN Serum bilirubin &lt; = 1.5 x ULN ( &lt; = 3.0 x ULN liver metastasis present ) Aspartate aminotransferase ( AST/SGOT ) , alanine aminotransferase ( ALT/SGPT ) &lt; = 3.0 x ULN ( &lt; = 5.0 x ULN liver metastasis present ) . Note : ERCP percutaneous stenting may use normalize liver function test . 11 . Life expectancy &gt; = 12 week 12 . Inclusion exclusion criterion DCEMRI DWI image determine CT scan part routine postchemotherapy imaging . Subjects eligible one liver metastasis great 1 cm size . Participation DCEMRI DWI correlate require eligibility . 13 . Ability give write informed consent accord local guideline 1 . DiseaseSpecific Exclusions 1 . Prior chemotherapy metastatic disease 2 . Prior full field radiotherapy &lt; = 4 week limited field radiotherapy &lt; = 2 week prior enrollment . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease . 3 . Prior biologic immunotherapy &lt; = 2 week prior registration . Patients must recover therapyrelated toxicity 4 . Prior therapy antiVEGF agent 5 . If history primary cancer , subject eligible : Curatively resect nonmelanomatous skin cancer Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present treatment administer last 3 year 6 . Concurrent use investigational agent patient receive investigational drug &lt; = 4 week prior enrollment . 7 . Hypersensitivity capecitabine , fluorouracil , component formulation know deficiency dihydropyrimidine dehydrogenase . 2 . General Medical Exclusions 1 . Subjects know chronic active hepatitis B C infection 2 . History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation study drug administration may interfere conduct study interpretation study result 3 . Male subject willing use adequate contraception upon enrollment study 6 month follow last dose secondline treatment 4 . Female subject ( childbearing potential , postmenopausal le 6 month , surgically sterilize , abstinent ) willing use oral , patch implant contraceptive , doublebarrier birth control , IUD course study 6 month follow last dose secondline treatment 5 . Female subject breastfeed positive serum pregnancy test 72 hour prior randomization 6 . Pleural effusion ascites cause respiratory compromise ( &gt; = CTCAE grade 2 dyspnea ) 7 . Any following concurrent severe and/or uncontrolled medical condition within 24 week enrollment could compromise participation study : Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction &lt; = 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung . Chronic renal disease Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) 8 . Patients unwilling unable comply protocol 9 . Life expectancy le 12 week 10 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study 3 . BevacizumabSpecific Exclusions 1 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) 2 . Any prior history hypertensive crisis hypertensive encephalopathy 3 . New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix A ) 4 . History myocardial infarction unstable angina within 6 month prior study enrollment 5 . History stroke transient ischemic attack within 6 month prior study enrollment 6 . Known CNS disease , brain metastasis . 7 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) 8 . Symptomatic peripheral vascular disease 9 . Evidence bleed diathesis coagulopathy 10 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study 11 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment 12 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment 13 . Serious , nonhealing wound , ulcer , bone fracture 14 . Urine protein &gt; = 2+ urinalysis dipstick &gt; = 1.0 gram 24hour urine collection 15 . Known hypersensitivity component bevacizumab 16 . History hemoptysis ( bright red blood Â½ teaspoon per episode ) within 3 month prior study enrollment . 17 . Current , ongoing treatment fulldose warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>